In a strategic move to fortify its oncology portfolio against looming patent expirations, MSD—known as Merck & Co. in the…
Read More
Novo Nordisk Expands Cardiometabolic Portfolio With $2.3bn Hengrui Licensing Deal for Once-Weekly Oral GLP-1/GIP Agonist HRS-1596
In a strategic move to cement its leadership in the booming cardiometabolic therapeutics market, Danish pharmaceutical titan Novo Nordisk has…
Read More
Tolerance Bio Secures Exclusive Global Rights Outside Japan for Tanabe Pharma Anti-IL-33 Monoclonal Antibody TLB-33 in Landmark $560m Deal
Tolerance Bio has finalized a high-stakes licensing agreement with Tanabe Pharma, acquiring exclusive worldwide commercialization rights—excluding Japan—for TLB-33, a clinical-stage…
Read More
AstraZeneca Deepens Oncology Footprint with $2bn Equity Investment in Summit Therapeutics to Advance Next-Generation Cancer Combinations
AstraZeneca has announced a landmark $2bn equity investment in Summit Therapeutics, marking a major strategic alignment between the pharmaceutical giants…
Read More
Daiichi Sankyo and Merck Voluntarily Withdraw US Application for Lung Cancer Drug Ifinatamab Deruxtecan Following FDA Discussions
Pharmaceutical giants Daiichi Sankyo and Merck & Co., known globally as MSD, have officially announced the voluntary withdrawal of their…
Read More
Novo Nordisk Secures $1.33bn Nanexa Licensing Deal to Accelerate Long-Acting Cardiometabolic Therapies
The global pharmaceutical landscape is undergoing a profound structural evolution, driven by surging demand for treatments addressing obesity, type 2…
Read More
Navigating the Evolution of Oral Solid Dose Pharmaceuticals: CDMOs and Sponsors Face New Demands in Packaging, Sustainability, and Scaling
The pharmaceutical landscape is undergoing a structural realignment, anchored by the resurgence of oral solid dosage (OSD) platforms and the…
Read More
FDA Approval of Tavapadon (Juvmo) Validates AbbVie’s $8.7bn Cerevel Takeover and Ushers in a New Era for Parkinson’s Treatment
The United States Food and Drug Administration has officially approved tavapadon, a next-generation dopamine-based therapy developed for the management of…
Read More
Enveda Biosciences Secures $311m in Series E Funding to Accelerate AI-Powered Natural Drug Discovery Pipeline
Colorado-based biotechnology pioneer Enveda Biosciences has officially closed a substantial $311m Series E financing round, bringing its cumulative venture backing…
Read More
Sandoz Charts a Bold Course to 2040 with the Bio100 Strategy to Dominate the Global Biosimilar Market
Global pharmaceutical giant Sandoz is undergoing a profound strategic evolution, shifting its long-term commercial anchor away from traditional small-molecule generics…
Read More
